Endeavor BioMedicines Presents New Clinical Findings From Post Hoc Analysis of Phase 2a Clinical Trial Evaluating ENV-101 in Patients with Idiopathic Pulmonary Fibrosis | Endeavor BioMedicines

endeavorbiomedicines.com/endeavor-bio... Encouraging results from Endeavor in a Phase 2a clinical trial for Idiopathic Pulmonary Fibrosis (IPF)! With few good treatment options, it is great to see positive data. #SanDiego #Biotech #IPF #EndeavorBioMed